ipopba/iStock via Getty Images
Flexion Therapeutics (NASDAQ:FLXN) continues to report steady revenue growth as ZILRETTA moves deeper into commercialization. Despite the ongoing pandemic, Flexion reported encouraging Q1 earnings that revealed commercial…
